Accepted answer
The 25% figure is real, but it is a derived ratio from one substudy rather than a measured constant, and it is routinely quoted with more authority than it deserves.
Where it comes from: the SURMOUNT-1 DEXA substudy reported that tirzepatide reduced total fat mass by about 33.9% and lean mass by about 10.9% in relative terms, which the authors summarised as roughly a 3:1 ratio of fat to lean tissue lost [1]. Convert the ratio to a share and you get the number everyone repeats:
fat : lean = 3 : 1
lean share = 1 / (3 + 1) = 0.25 = 25% of tissue lost
So "a quarter" is arithmetic performed on a single substudy's summary ratio. It is not wrong, but it is a central estimate from one drug, one dose range, one population, one scan modality.
What the substudies actually report
| Programme | DEXA subgroup | Duration | Reported body-composition finding | Implied lean share of tissue lost |
| SURMOUNT-1 substudy | ~160 | 72 weeks | Fat mass down ~33.9%, lean mass down ~10.9%; fat:lean ratio ~3:1 | ~25% |
| STEP 1 substudy | ~140 | 68 weeks | Fat mass fell as a proportion of body mass by ~3.5 percentage points; visceral fat down ~27%; lean mass share of body weight rose | ~30-40% depending on whether you use lean soft tissue or fat-free mass |
| Liraglutide vs exercise vs both | 195 randomised | 52 weeks | Lean mass preserved in the arms containing exercise; drug-alone arm lost lean mass | Modality-dependent, not drug-dependent |
| Diet-only caloric restriction (historical benchmark) | - | 3-12 months | Classic figure for moderate deficits without training | ~20-30% |
| Roux-en-Y gastric bypass (historical benchmark) | - | 12 months | Much larger absolute losses, similar proportion | ~25-30% |
Notice what that table does not show: a GLP-1-specific muscle-sparing effect. The proportion is in the same band as diet-only restriction and the same band as surgery. The drug changes how much total tissue you lose and how easy the deficit is to sustain. It does not appear to change the fat-to-lean split much on its own. Anyone selling you the incretin as a muscle-sparing agent is over-reading the data.
Applying it to your 11.2 kg, with caveats
Naive application: 11.2 kg x 0.25 = 2.8 kg of lean soft tissue. That is the number you were probably expecting.
Two reasons the real figure is likely lower than that at week 14. First, the Forbes relationship: the fatter you are at baseline, the smaller the lean fraction of what you lose. At 104.6 kg you were almost certainly carrying enough fat mass to sit at the favourable end of that curve, which pushes you below 25%. Second, early loss is disproportionately water and glycogen, and DEXA scores both as lean soft tissue. The answer below works that arithmetic out; briefly, 2 kg of the "lean" in a fast first three months can be non-contractile.
My working estimate for someone in your position with adequate protein and any resistance stimulus is 1.2-2.0 kg of true lean soft tissue at week 14, of which some fraction is water. Without a baseline scan that is an estimate, not a measurement, and you should treat it as such.
edited 21 Apr 2025 by gradient_slope — added a caveat about sampling
4The Forbes point is the one people skip. Lean fraction is not a constant, it is a function of starting fat mass. – coldpack_88 8 months ago 5Also worth noting the SURMOUNT-1 substudy was not powered to compare doses, so per-dose lean figures do not exist. – mateo_iglesias 1 days ago add a comment